Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Antibióticos para tratar enfermedades causadas por Helicobacter

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20190624001
Publicado:
26/07/2019
Caducidad:
26/07/2020
Resumen:
Un centro de investigación español, en colaboración con otros copropietarios, ha desarrollado derivados químicos que actúan selectivamente contra la bacteria Helicobacter pylori y permiten reducir la carga bacteriana e incluso erradicar infecciones gástricas causadas por la bacteria. La bacteria Helicobacter pylori causa infecciones asintomáticas en la mucosa gástrica que dan lugar a gastritis crónica, úlceras e incluso cáncer gástrico. Los derivados de benzo [c] [1,2,5]oxadiazol son antimicrobianos que actúan individualmente (sin combinación con otros fármacos) y selectivamente y atacan una enzima específica de la bacteria, su flavodoxina. La enzima no está presente en humanos, evitando posibles daños secundarios. El centro de investigación busca socios de la industria farmacéutica con el fin de licenciar la patente.

Details

Tittle:
Antibiotics to treat diseases caused by Helicobacter
Summary:
A Spanish research institution in collaboration with other co-owners have developed chemical derivatives that act selectively against the bacterium Helicobacter pylori, managing to reduce the bacterial load and even eradicate gastric infections caused by it.

Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement.
Description:
Derivatives without resistance against gastric infections.

The bacterium Helicobacter pylori (Hp) causes asymptomatic infections in the gastric mucosa that can induce chronic gastritis, ulcers even gastric cáncer. So far, conventional therapies are aggressive and the rate of eradication is decreasing, as Hp is increasingly resistant to such treatment.
Derivatives of benzo [c] [1,2,5]oxadiazol (Figure 1) are antimicrobials that act individually (without combination with other drugs) and selectively, attack a specific enzyme of the bacterium, its flavodoxine. In humans the enzyme is not present, so possible secondary damage is avoided.
The results obtained in mice have been, reduced rates of gastric colonization of Hp and even eradication in up to 60% of mice.

Industrial partner is being sought to collaborate through a patent license agreement. The partner role will be: (i) produce the cells and, (ii) commercialize the cells.
Advantages and Innovations:
Then main advantages are:
1. New antibiotics without known resistances.
2. Efficacy in resistant strains.
3. Safety: no toxicity at their active concentrations.
4. Low cost synthesis.
5. Bactericidal activity at low concentrations.
6. Current status, in vitro: toxicity in cells and in vivo: both toxicity and efficacy test in mice.
Stage of Development:
Under development/lab tested
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
Spanish patent application filed

Partner sought

Type and Role of Partner Sought:
Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement. The partner role will be: (i) produce the antibiotics and, (ii) commercialize the antibiotics.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001015 Productos farmacéuticos / medicamentos
06001018 Virus, virología / antibióticos / bacteriología